hospital covid-19 patient

COVID-19 Scan for Jul 15, 2021

Reading now: 173
www.cidrap.umn.edu

Early monoclonal antibody combo for COVID-19 cuts hospital, death ratesYesterday in the New England Journal of Medicine results from a phase 3 trial showed that a combination of bamlanivimab plus etesevimab monoclonal antibodies led to a lower incidence of COVID-19–related hospitalization and deaths.The therapy also accelerated the decline in the SARS-CoV-2 viral load in patients who received the treatment, if administered within 3 days of diagnosis of mild to moderate COVID-19 in patients with at least one risk factor for developing serious disease.The trial including 1,095 patients who either received a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2,800 milligrams [mg] of bamlanivimab and

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News